Group I Intron-Based Therapeutics Through Trans-Splicing Reaction.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Progress in Molecular Biology and Translational Science

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/bs.pmbts.2018.07.001PMID 30340790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic genome engineering via CRISPR‐Cas systems

  2017cited by this paper
• Refining strategies to translate genome editing to the clinic

  2017cited by this paper
• CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes.

  2017cited by this paper
• Advances in the delivery of RNA therapeutics: from concept to clinical reality

  2017cited by this paper
• Engineered CRISPR Systems for Next Generation Gene Therapies.

  2017cited by this paper
• Delivery technologies for genome editing

  2017cited by this paper
• CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes.

  2017cited by this paper
• Design and Experimental Evolution of trans-Splicing Group I Intron Ribozymes

  2017cited by this paper
• Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.

  2017cited by this paper
• Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.

  2016cited by this paper
• Applications of CRISPR technologies in research and beyond

  2016cited by this paper
• Image-aided Suicide Gene Therapy Utilizing Multifunctional hTERT-targeting Adenovirus for Clinical Translation in Hepatocellular Carcinoma

  2016cited by this paper
• Gene therapy returns to centre stage

  2015cited by this paper
• Increased efficiency of evolved group I intron spliceozymes by decreased side product formation

  2015cited by this paper
• Orthogonal gene knock out and activation with a catalytically active Cas9 nuclease

  2015cited by this paper
• Targeted Regression of Hepatocellular Carcinoma by Cancer-Specific RNA Replacement through MicroRNA Regulation

  2015cited by this paper
• Therapeutic genome editing: prospects and challenges

  2015cited by this paper
• Targeted anticancer effect through microRNA-181a regulated tumor-specific hTERT replacement.

  2015cited by this paper
• The new frontier of genome engineering with CRISPR-Cas9

  2014cited by this paper
• Efficient targeting and tumor retardation effect of pancreatic adenocarcinoma up-regulated factor (PAUF)-specific RNA replacement in pancreatic cancer mouse model.

  2014cited by this paper
• Use of tumor-targeting trans-splicing ribozyme for cancer treatment.

  2014cited by this paper
• Effective suppression of Dengue virus using a novel group-I intron that induces apoptotic cell death upon infection through conditional expression of the Bax C-terminal domain

  2014cited by this paper
• Conditional and target-specific transgene induction through RNA replacement using an allosteric trans-splicing ribozyme.

  2014cited by this paper
• Development and applications of CRISPR-Cas9 for genome engineering.

  2014cited by this paper
• In Vivo Evolution of a Catalytic RNA Couples Trans-Splicing to Translation

  2014cited by this paper
• Multiplex Genome Engineering Using CRISPR/Cas Systems

  2013cited by this paper
• ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

  2013cited by this paper
• Gene therapy on the move

  2013cited by this paper
• One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering.

  2013cited by this paper
• Hepatitis C Virus RNA Replication

  2013cited by this paper
• Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.

  2013cited by this paper
• An in vivo selection method to optimize trans-splicing ribozymes.

  2012cited by this paper
• Computational prediction of efficient splice sites for trans-splicing ribozymes.

  2012cited by this paper
• Cancer-specific induction of adenoviral E1A expression by group I intron-based trans-splicing ribozyme.

  2012cited by this paper
• Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by trans-splicing ribozyme.

  2012cited by this paper
• RNA-based therapeutics: current progress and future prospects.

  2012cited by this paper
• Cancer-Associated Splicing Variant of Tumor Suppressor AIMP2/p38: Pathological Implication in Tumorigenesis

  2011cited by this paper
• Cryptic genetic variation promotes rapid evolutionary adaptation in an RNA enzyme

  2011cited by this paper
• Selective and efficient retardation of cancers expressing cytoskeleton‐associated protein 2 by targeted RNA replacement

  2011cited by this paper
• Ras in cancer and developmental diseases.

  2011cited by this paper
• Intracellular efficacy of tumor‐targeting group I intron‐based trans‐splicing ribozyme

  2011cited by this paper
• Targeting of highly conserved Dengue virus sequences with anti-Dengue virus trans-splicing group I introns

  2010cited by this paper
• RNA reprogramming and repair based on trans-splicing group I ribozymes.

  2010cited by this paper
• RNA as a drug target: recent patents on the catalytic activity of trans-splicing ribozymes derived from group I intron RNA.

  2010cited by this paper
• RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

  2010cited by this paper
• Cancer cell targeting with mouse TERT-specific group I intron of Tetrahymena thermophila.

  2009cited by this paper
• Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo

  2009cited by this paper
• Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties

  2009cited by this paper
• Imaging Target mRNA and siRNA‐Mediated Gene Silencing In Vivo with Ribozyme‐Based Reporters

  2008cited by this paper
• A Pneumocystis carinii group I intron-derived ribozyme utilizes an endogenous guanosine as the first reaction step nucleophile in the trans excision-splicing reaction.

  2008cited by this paper
• Tetrahymena thermophila and Candida albicans Group I intron-derived ribozymes can catalyze the trans-excision-splicing reaction

  2008cited by this paper
• Tumor cell apoptosis induces tumor‐specific immunity in a CC chemokine receptor 1‐ and 5‐dependent manner in mice

  2008cited by this paper
• In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells.

  2008cited by this paper
• Antitumor Effects of Systemically Delivered Adenovirus Harboring Trans-Splicing Ribozyme in Intrahepatic Colon Cancer Mouse Model

  2008cited by this paper
• Ribozymes, riboswitches and beyond: regulation of gene expression without proteins

  2007cited by this paper
• Targeted retardation of hepatocarcinoma cells by specific replacement of alpha-fetoprotein RNA.

  2007cited by this paper
• Molecular imaging of endogenous mRNA expression in a mouse tumor model by adenovirus harboring trans‐splicing ribozyme

  2007cited by this paper
• Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme

  2007cited by this paper
• Selective Regression of Cells Expressing Mouse Cytoskeleton-Associated Protein 2 Transcript by Trans-Splicing Ribozyme

  2007cited by this paper
• Hematopoietic-specific microRNA expression in human cells.

  2006cited by this paper
• Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

  2006cited by this paper
• Atomic level architecture of group I introns revealed.

  2006cited by this paper
• Cancer‐selective induction of cytotoxicity by tissue‐specific expression of targeted trans‐splicing ribozyme

  2006cited by this paper
• CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control

  2006cited by this paper
• RNA reprogramming of α‐mannosidase mRNA sequences in vitro by myxomycete group IC1 and IE ribozymes

  2006cited by this paper
• RNA splicing: group I intron crystal structures reveal the basis of splice site selection and metal ion catalysis.

  2006cited by this paper
• Ribozyme-mediated selective killing of cancer cells expressing carcinoembryonic antigen RNA by targeted trans-splicing.

  2006cited by this paper
• Ribozyme: a clinical tool.

  2006cited by this paper
• Tumor-specific gene delivery using RNA-targeting Tetrahymena group I intron

  2005cited by this paper
• Crystal structure of a phage Twort group I ribozyme–product complex

  2005cited by this paper
• Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript.

  2005cited by this paper
• Optimization and application of the group I ribozyme trans-splicing reaction.

  2004cited by this paper
• Structure of the Tetrahymena ribozyme: base triple sandwich and metal ion at the active site.

  2004cited by this paper
• Restoration of protein synthesis in pancreatic cancer cells by trans-splicing ribozymes.

  2004cited by this paper
• Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA.

  2004cited by this paper
• Crystal structure of a self-splicing group I intron with both exons

  2004cited by this paper
• Intracellular folding of the Tetrahymena group I intron depends on exon sequence and promoter choice.

  2004cited by this paper
• Single-cell detection of trans-splicing ribozyme in vivo activity.

  2004cited by this paper
• MicroRNAs Modulate Hematopoietic Lineage Differentiation

  2004cited by this paper
• Crystal structure of a group I intron splicing intermediate.

  2004cited by this paper
• Artificial Modules for Enhancing Rate Constants of a Group I Intron Ribozyme without a P4-P6 Core Element*

  2004cited by this paper
• Ribozymes: recent advances in the development of RNA tools.

  2003cited by this paper
• Identification of the most accessible sites to ribozymes on the hepatitis C virus internal ribosome entry site.

  2003cited by this paper
• N-terminal deletion augments the cell-death-inducing activity of BAX in adenoviral gene delivery to nonsmall cell lung cancers

  2003cited by this paper
• Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes.

  2003cited by this paper
• Telomerase and tumorigenesis.

  2003cited by this paper
• Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry site-expressing cells by targeted trans-splicing.

  2003cited by this paper
• Ribozyme-mediated revision of RNA and DNA.

  2003cited by this paper
• Efficient and specific repair of sickle β-globin RNA by trans-splicing ribozymes

  2003cited by this paper
• Telomerase modulates expression of growth-controlling genes and enhances cell proliferation

  2003cited by this paper
• Approaches for the sequence-specific knockdown of mRNA

  2003cited by this paper
• Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again.

  2002cited by this paper
• In vivo selection of better self-splicing introns in Escherichia coli: the role of the P1 extension helix of the Tetrahymena intron.

  2002cited by this paper
• Distribution of rRNA introns in the three-dimensional structure of the ribosome.

  2002cited by this paper
• Functional repair of a mutant chloride channel using a trans-splicing ribozyme.

  2002cited by this paper
• Optimization of trans-splicing ribozyme efficiency and specificity by in vivo genetic selection.

  2002cited by this paper
• Telomerase: a target for cancer therapeutics.

  2002cited by this paper
• Cancer gene therapy: fringe or cutting edge?

  2001cited by this paper
• Ribozyme gene therapy: applications for molecular medicine.

  2001cited by this paper
• AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits

  2001cited by this paper

• Synthetic circRNA therapeutics: innovations, strategies, and future horizons

  2024cites this paper
• Organellar Introns in Fungi, Algae, and Plants

  2021cites this paper
• RGEN Editing of RNA and DNA: The Long and Winding Road from Catalytic RNAs to CRISPR to the Clinic.

  2020cites this paper